The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A systematic review of geographical variation in access to chemotherapy
Open accessAbstract
BACKGROUND: Rising cancer incidence, the cost of cancer pharmaceuticals and the introduction of the Cancer Drugs Fund in England, but not other United Kingdom(UK) countries means evidence of 'postcode prescribing' in cancer is important. There have been no systematic reviews considering access to cancer drugs by geographical characteristics in the UK. METHODS: Studies describing receipt of cancer drugs, according to healthcare boundaries (e.g. cancer network [UK]) were identified through a systematic search of electronic databases and grey literature. Due to study heterogeneity a meta-analysis was not possible and a narrative synthesis was performed. RESULTS: 8,780 unique studies were identified and twenty-six included following a systematic search last updated in 2015. The majority of papers demonstrated substantial variability in the likelihood of receiving chemotherapy between hospitals, health authorities, cancer networks and UK countries (England and Wales). After case-mix adjustment, there was up to a 4-5 fold difference in chemotherapy utilisation between the highest and lowest prescribing cancer networks. There was no strong evidence that rurality or distance travelled were associated with the likelihood of receiving chemotherapy and conflicting evidence for an effect of travel time. CONCLUSIONS: Considerable variation in chemotherapy prescribing between healthcare boundaries has been identified. The absence of associations with natural geographical characteristics (e.g. rurality) and receipt of chemotherapy suggests that local treatment habits, capacity and policy are more influential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Health service coverage and its evaluation.
Tanahashi, T. (1978) · Europe PMC (PubMed Central) · Cited by 503
Equitable access to cancer services: A review of barriers to quality care.
Mandelblatt, J. S., Yabroff, K. R., & Kerner, J. F. (1999) · PubMed · Cited by 247
Equitable access to cancer services: A review of barriers to quality care
Mandelblatt, J. S., Yabroff, K. R., & Kerner, J. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11<2378::aid-cncr28>3.0.co;2-l · Cited by 223
Transportation as a barrier to cancer treatment.
Guidry, J. J., Aday, L. A., Zhang, D., & Winn, R. (1997) · PubMed · Cited by 203
Impact of Referral Patterns on the Use of Chemotherapy for Lung Cancer
Earle, C. C., Neumann, P. J., Gelber, R. D., Weinstein, M. C., & Weeks, J. C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.142 · Cited by 176
Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer
Jones, A. P., Haynes, R., Sauerzapf, V., Crawford, S. M., Zhao, H., & Forman, D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.001 · Cited by 164
Effect of Nurse Case Management on the Treatment of Older Women with Breast Cancer
Goodwin, J. S., Satish, S., Anderson, E. T., et al. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51409.x · Cited by 134
Cited by
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Quintero-Fabián, S., Arreola, R., Becerril-Villanueva, E., Torres-Romero, J. C., Arana-Argáez, V., Lara-Riegos, J., Ramírez-Camacho, M. A., & Alvarez-Sánchez, M. E. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01370 · Cited by 1,036
Oral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 831
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Nanomedicine review: clinical developments in liposomal applications
Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 513
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
Metadata
- Authors
- Chamberlain, C., Owen-Smith, A., Donovan, J., & Hollingworth, W.
- Venue
- BMC Cancer
- Published
- 2015-12-31
- Volume
- 16
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2205275114
- Cited by
- 390
- References
- 30
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review of geographical variation in access to chemotherapy. https://app.cochat.ai/papers/10.1186/s12885-015-2026-y
- The paper
- Chamberlain, C., Owen-Smith, A., Donovan, J., & Hollingworth, W. (2016). A systematic review of geographical variation in access to chemotherapy. BMC Cancer. https://doi.org/10.1186/s12885-015-2026-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.